Navigation Links
‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread
Date:9/2/2014

Breast cancer cells can lay the groundwork for their own spread throughout the body by coaxing cells within lymphatic vessels to send out tumor-welcoming signals, according to a new report by Johns Hopkins scientists.

Writing in the Sept. 2 issue of Nature Communications, the researchers describe animal and cell-culture experiments that show increased levels of so-called signaling molecules released by breast cancer cells. These molecules cause lymphatic endothelial cells (LECs) in the lungs and lymph nodes to produce proteins called CCL5 and VEGF. CCL5 attracts tumor cells to the lungs and lymph nodes, and VEGF increases the number of blood vessels and makes them more porous, allowing tumor cells to metastasize and infiltrate the lungs.

In the same report, the researchers say maraviroc, a drug already approved for treating HIV infection, blocked the siren call of CCL5 in tests on animals and cells and prevented tumor spread (metastasis). Additional experiments using a combination of maraviroc and a drug that blocks the VEGF protein suggest that the treatment duo could be an effective way to prevent metastatic disease in human breast cancer patients, according to the researchers.

Because the anti-retroviral drug maraviroc has already been approved by the U.S. Food and Drug Administration and has been shown safe for long term, oral use, it could be tested in clinical trials sooner rather than later, says Aleksander Popel, Ph.D., a professor in the Department of Biomedical Engineering at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center.

"It was surprising to find that LECs can play such an active and significant role in tumor spread." Popel noted. "Conventionally, lymphatic vessels are regarded mainly as passive conduits through which tumor cells spread from the primary tumor and eventually metastasize," he said. "However, we now know that lymphatic vessels enable metastasis, and other studies also show that they play an important role in whether or not immune cells recognize and attack cancer cells."

Popel and colleagues traced the influence of tumor signaling on LECs in cell cultures and in mice. Breast cancer cells were bathed in a nutrient-rich liquid, and, as the cancer cells grew, the investigators detected secretions of a signaling molecule called interleukin-6 (IL6) in the liquid.

Mice that were injected with the IL6-containing liquid experienced a continual rise in CCL5 levels in blood samples for several weeks. Nine of 10 tumor-bearing mice injected with the IL6-laden liquid developed metastases five weeks later. Only two of 10 mice, exposed to the liquid and given a combination of maraviroc and a VEGF-blocking drug, developed metastases.

Because maraviroc blocks the actions of CCL5, it could be delivered, along with standard chemotherapy, right after surgically removing a tumor in a bid to prevent any leftover circulating tumor cells from finding a new metastatic niche in the body, Popel says.

"However, IL6-secreting tumors could be laying the groundwork for metastasis much earlier than surgery occurs in a patient," he said. "To prevent metastatic sites from taking root, we could administer drugs that block IL6 before surgery."

The study did not address when or how to remove lymph node tissue surgically, as is often done as part of breast cancer treatment, but Popel and colleagues hope to explore the issue in future studies.


'/>"/>

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine
Source:Eurekalert

Related medicine news :

1. Atlantic NeuroSurgical Specialists (ANS) Introduce Noninvasive Treatment for Brain Tumor Patients
2. Circulating tumor cell clusters more likely to cause metastasis than single cells
3. American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators
4. Preclinical development of tumor therapeutic agent starts
5. Tumor blood vessel protein provides potential therapeutic target
6. High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer
7. Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma
8. Patient, tumor characteristics for high-mitotic rate melanoma
9. Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice
10. Massachussetts General-developed device monitors key step in development of tumor metastases
11. Myc inhibition is an effective therapeutic strategy against most aggressive brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 05, 2016 , ... Qrono Inc. , a specialty ... collaboration with the Australian critical medicine company, Phebra Pty Ltd. , to ... medicines can offer improved therapeutic benefits over oral formulations, including better bioavailability, improved ...
(Date:5/5/2016)... ... , ... Einstein Medical is proud to announce that it has ... commentary at the 2016 ASCRS/ASOA Symposium and Congress, which takes place in New Orleans, ... Refractive Surgery and the American Society of Ophthalmic Administrations will be held at the ...
(Date:5/5/2016)... Francisco, CA (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, May ... will take on steep California terrain at the first Team Semper Fi Mountain Bike Camp, ... Joining them will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... Business Journalists , led by the Wharton School’s most prominent professors, help ... one-day program at the Wharton School’s San Francisco campus will feature Wharton ...
(Date:5/5/2016)... ... May 05, 2016 , ... Derrin Doty Group has ... of Bremerton, Port Orchard and communities west of Seattle. The insurance provider’s caring team ... local girl who died suddenly due to complications from the flu, that they have ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
Breaking Medicine Technology: